DexCom
Trade DexCom 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About DXCM
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.
DXCM Key Statistics
Stock Snapshot
With a market cap of 27.12B, DexCom(DXCM) trades at $68.77. The stock has a price-to-earnings ratio of 38.70.
As of 2026-01-18, DexCom(DXCM) stock has fluctuated between $68.77 and $70.37. The current price stands at $68.77, placing the stock 0.0% above today's low and -2.3% off the high.
The DexCom(DXCM)'s current trading volume is 7.44M, compared to an average daily volume of 6.52M.
In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.
In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.
DXCM News
DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust preliminary results, the company’s shares ha...
DexCom recently reported preliminary, unaudited fourth-quarter 2025 revenue of about US$1.26 billion, up 13% year over year, and full-year 2025 revenue of rough...
If you are wondering whether DexCom's current share price lines up with its underlying worth, this article will walk through what the numbers are really saying...
Analyst ratings
85%
of 33 ratingsMore DXCM News
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #56 analyst pick, m...
In early trading on Monday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Dex...
Barclays downgraded DexCom (DXCM) to Underweight from Equal Weight with a price target of $71, down from $80. The firm expects competition in DexCom’s core insu...
Reports preliminary FY25 revenue $4.66B, consensus $4.64B. “We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance a...
Advertisement Conference spotlight and mixed analyst signals DexCom (DXCM) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 1...